GlassScriptPhysician profile
Katharine Mikulec
NPI 1336254887
$3,535.56
in general payments reported to CMS, 2019-2025
32 companies · $920 in 2025
The $920 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $221 · 2021: $246 · 2022: $422 · 2023: $589 · 2024: $644 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,152.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,125.08 | 2019-2025 | Evenity, Prolia, Prolia |
| Radius Health, INC. | $921.79 | 2019-2025 | Tymlos |
| Novo Nordisk INC | $224.79 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $173.38 | 2019-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $156.56 | 2023-2025 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $117.26 | 2019-2025 | Strensiq |
| Amneal Pharmaceuticals LLC | $61.41 | 2021-2022 | |
| Daiichi Sankyo INC. | $59.71 | 2019-2024 | Injectafer |
| Abbvie INC. | $59.00 | 2022-2025 | |
| Adlon Therapeutics L.P. | $54.25 | 2020-2021 | |
| Pfizer INC. | $53.56 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $47.76 | 2023-2024 | |
| Ascendis Pharma Endocrinology INC | $47.02 | 2024-2025 | Yorvipath |
| Biohaven Pharmaceutical Holding Company LTD. | $45.15 | 2022 | |
| Amarin Pharma, INC. | $37.18 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $36.78 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $34.19 | 2023-2025 | Evusheld, Airsupra |
| Corcept Therapeutics | $31.85 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $28.89 | 2022-2023 | Quviviq |
| Ultragenyx Pharmaceutical INC. | $28.73 | 2023 | |
| Inspire Medical Systems, INC. | $22.45 | 2025 | Inspire |
| Abbott Laboratories | $21.45 | 2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $20.08 | 2024 | Spravato |
| Tris Pharma INC | $17.83 | 2025 | Dyanavel Xr |
| Kyowa Kirin, INC. | $16.56 | 2024 | Crysvita |
| Ascend Therapeutics US, LLC | $16.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.40 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.80 | 2022 | |
| Almatica Pharma LLC | $13.33 | 2024 | Loreev Xr, Teriparatide |
| Merck Sharp & Dohme LLC | $12.77 | 2023 | Verquvo, Belsomra, Januvia |
| Kowa Pharmaceuticals America, INC. | $11.36 | 2020 | |
| Currax Pharmaceuticals LLC | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katharine Mikulec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.